Redox-metabolic circuits as a central regulator of T cell-based immunotherapy
-
By
-
Sarah McPhedran
-
Tian Zhao
-
Julian J. Lum
-
May 14, 2026
-
Clinical Scorecard: Metabolic and Redox Pathways as Key Regulators in T Cell Immunotherapy
At a Glance
| Category | Detail |
|---|
| Condition | |
| Key Mechanisms | Reactive oxygen species (ROS), methionine metabolism, GCN2 signaling, transsulfuration pathway |
| Target Population | |
| Care Setting | |
Key Highlights
- T cell metabolism shifts based on differentiation state and functional capacity.
- Physiological ROS are crucial for T cell receptor signaling and cytotoxicity.
- Excessive oxidative stress can lead to T cell exhaustion and apoptosis.
- GCN2 links amino acid availability to T cell metabolic programs.
- Therapeutic manipulation of metabolic pathways can enhance immunotherapy outcomes.
- Amino acid deprivation stimulates ROS accumulation.
Guideline-Based Recommendations
Diagnosis
Management
- Consider metabolic engineering and pharmacological interventions to enhance T cell function, including specific drugs targeting ROS and GCN2.
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients with solid tumors receiving T cell-based therapies.
Modulating methionine availability and GCN2 signaling may improve therapeutic outcomes.
Clinical Best Practices
- Utilize integrated omics and CRISPR-based screening to identify metabolic targets.
- Implement context-aware metabolic interventions tailored to individual patient needs.
- Regularly assess redox state and nutrient availability in T cells, including monitoring oxidative stress.
Related Resources & Content
